{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:53:38Z","timestamp":1781654018142,"version":"3.54.5"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Polygenic risk scores (PRS), metabolomics, and proteomics have each shown promise in improving type 2 diabetes risk prediction, but their combined utility beyond established clinical models remains unclear. We aimed to evaluate whether integrating multi-omics biomarkers enhances 10-year type 2 diabetes risk prediction beyond single-omics extensions and the clinical Cambridge Diabetes Risk Score (CDRS), which includes HbA\n                      <jats:sub>1c<\/jats:sub>\n                      measurements.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analysed data from 42,840 UK Biobank participants without diagnosed diabetes at baseline. The study population was split into a derivation set (Phase 1 metabolomics release,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200923,108) to fit models and an independent validation set (Phase 2 release,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200919,732) to evaluate performance. Data for a PRS for type 2 diabetes, 11 metabolites, and 15 proteins were added to the CDRS to develop multi-omics prediction models. Model performance was evaluated using Harrell\u2019s C-index and the net reclassification index (NRI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During 10 years of follow-up, 1090 participants developed incident type 2 diabetes. Among individual omics layers, proteomics contributed the greatest improvement in predictive performance, increasing the C-index from 0.862 (clinical CDRS) to 0.884 (\u0394C-index; + 0.022;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), with a continuous NRI of 42.0%. The full multi-omics model further significantly increased the C-index compared to a model combining the clinical CDRS with proteomics data (C-index, 0.891; \u0394C-index; + 0.007;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Integrating proteomics, metabolomics, and a diabetes-PRS into a clinical model substantially improves type 2 diabetes risk prediction beyond single-omics extensions. Several of the selected proteins and metabolites are on cardiovascular disease pathways, highlighting the link between diabetes and cardiovascular risk. However, the C-index difference between the proteomics extended and full multi-omics extended models is small, and the clinical models extended with proteomics data would be easier to translate into routine care because it needs only the measurement of 15 proteins. External validation and cost-effectiveness analyses are needed to support clinical adoption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-026-03223-y","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:16:23Z","timestamp":1779948983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Large-scale multi-omics enhance risk prediction for type 2 diabetes"],"prefix":"10.1186","volume":"25","author":[{"given":"Ruijie","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Sch\u00f6ttker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"10397","key":"3223_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"regional Global","year":"2023","unstructured":"Global regional, national burden of diabetes. from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203\u201334.","journal-title":"Lancet"},{"issue":"10365","key":"3223_CR2","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400(10365):1803\u201320.","journal-title":"Lancet"},{"issue":"9","key":"3223_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","volume":"18","author":"D Tomic","year":"2022","unstructured":"Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022;18(9):525\u201339.","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"3223_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"DPPR Group","year":"2002","unstructured":"Group DPPR. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393\u2013403.","journal-title":"N Engl J Med"},{"issue":"18","key":"3223_CR5","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","volume":"344","author":"J Tuomilehto","year":"2001","unstructured":"Tuomilehto J, Lindstr\u00f6m J, Eriksson JG, Valle TT, H\u00e4m\u00e4l\u00e4inen H, Ilanne-Parikka P, Kein\u00e4nen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343\u201350.","journal-title":"N Engl J Med"},{"key":"3223_CR6","doi-asserted-by":"publisher","first-page":"e5900","DOI":"10.1136\/bmj.e5900","volume":"345","author":"A Abbasi","year":"2012","unstructured":"Abbasi A, Peelen LM, Corpeleijn E, van der Schouw YT, Stolk RP, Spijkerman AM, van der Moons AD, Navis KG, Bakker G. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. BMJ. 2012;345:e5900.","journal-title":"BMJ"},{"key":"3223_CR7","doi-asserted-by":"publisher","first-page":"j5019","DOI":"10.1136\/bmj.j5019","volume":"359","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C. Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study. BMJ. 2017;359:j5019.","journal-title":"BMJ"},{"issue":"10138","key":"3223_CR8","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1016\/S0140-6736(18)31132-2","volume":"391","author":"C Langenberg","year":"2018","unstructured":"Langenberg C, Lotta LA. Genomic insights into the causes of type 2 diabetes. Lancet. 2018;391(10138):2463\u201374.","journal-title":"Lancet"},{"key":"3223_CR9","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00125-018-4599-x","volume":"61","author":"J Merino","year":"2018","unstructured":"Merino J, Leong A, Liu C-T, Porneala B, Walford GA, von Grotthuss M, Wang TJ, Flannick J, Dupuis J, Levy D. Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose. Diabetologia. 2018;61:1315\u201324.","journal-title":"Diabetologia"},{"issue":"11","key":"3223_CR10","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/s41591-022-02055-z","volume":"28","author":"J Carrasco-Zanini","year":"2022","unstructured":"Carrasco-Zanini J, Pietzner M, Lindbohm JV, Wheeler E, Oerton E, Kerrison N, Simpson M, Westacott M, Drolet D, Kivimaki M. Proteomic signatures for identification of impaired glucose tolerance. Nat Med. 2022;28(11):2293\u2013300.","journal-title":"Nat Med"},{"issue":"8003","key":"3223_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41586-024-07019-6","volume":"627","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Hatzikotoulas K, Southam L, Taylor HJ, Yin X, Lorenz KM, Mandla R, Huerta-Chagoya A, Melloni GEM, Kanoni S, et al. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature. 2024;627(8003):347\u201357.","journal-title":"Nature"},{"issue":"1","key":"3223_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-8587(13)70143-8","volume":"2","author":"LD Roberts","year":"2014","unstructured":"Roberts LD, Koulman A, Griffin JL. Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome. lancet Diabetes Endocrinol. 2014;2(1):65\u201375.","journal-title":"lancet Diabetes Endocrinol"},{"issue":"11","key":"3223_CR13","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1161\/CIRCRESAHA.120.315898","volume":"126","author":"ZZ Chen","year":"2020","unstructured":"Chen ZZ, Gerszten RE. Metabolomics and proteomics in type 2 diabetes. Circ Res. 2020;126(11):1613\u201327.","journal-title":"Circ Res"},{"issue":"21","key":"3223_CR14","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1056\/NEJMoa0804742","volume":"359","author":"JB Meigs","year":"2008","unstructured":"Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, Manning AK, Florez JC, Wilson PW. D\u2019Agostino Sr RB: Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359(21):2208\u201319.","journal-title":"N Engl J Med"},{"issue":"5","key":"3223_CR15","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.2337\/db14-1504","volume":"64","author":"PJ Talmud","year":"2015","unstructured":"Talmud PJ, Cooper JA, Morris RW, Dudbridge F, Shah T, Engmann J, Dale C, White J, McLachlan S, Zabaneh D. Sixty-five common genetic variants and prediction of type 2 diabetes. Diabetes. 2015;64(5):1830\u201340.","journal-title":"Diabetes"},{"issue":"4","key":"3223_CR16","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2337\/dc21-1705","volume":"45","author":"J Morze","year":"2022","unstructured":"Morze J, Wittenbecher C, Schwingshackl L, Danielewicz A, Rynkiewicz A, Hu FB, Guasch-Ferr\u00e9 M. Metabolomics and type 2 diabetes risk: an updated systematic review and meta-analysis of prospective cohort studies. Diabetes Care. 2022;45(4):1013\u201324.","journal-title":"Diabetes Care"},{"issue":"5","key":"3223_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00125-024-06097-5","volume":"67","author":"N Kurgan","year":"2024","unstructured":"Kurgan N, Kj\u00e6rgaard Larsen J, Deshmukh AS. Harnessing the power of proteomics in precision diabetes medicine. Diabetologia. 2024;67(5):783\u201397.","journal-title":"Diabetologia"},{"issue":"1","key":"3223_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00125-023-06027-x","volume":"67","author":"J Carrasco-Zanini","year":"2024","unstructured":"Carrasco-Zanini J, Pietzner M, Wheeler E, Kerrison ND, Langenberg C, Wareham NJ. Multi-omic prediction of incident type 2 diabetes. Diabetologia. 2024;67(1):102\u201312.","journal-title":"Diabetologia"},{"key":"3223_CR19","doi-asserted-by":"crossref","unstructured":"Xie R, Vlaski T, Trares K, Herder C, Holleczek B, Brenner H, Sch\u00f6ttker B. Large-scale proteomics improve risk prediction for type 2 diabetes. Diabetes Care 2025;48(6):922-926 .","DOI":"10.2337\/dc24-2478"},{"key":"3223_CR20","doi-asserted-by":"crossref","unstructured":"Xie R, Herder C, Sha S, Peng L, Brenner H, Schoettker B. Novel type 2 diabetes prediction score based on traditional risk factors and circulating metabolites: model derivation and validation in two large cohort studies. eClinicalMedicine 2025;79:102971.","DOI":"10.1016\/j.eclinm.2024.102971"},{"issue":"3","key":"3223_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/fampra\/cmn024","volume":"25","author":"M Rahman","year":"2008","unstructured":"Rahman M, Simmons RK, Harding AH, Wareham NJ, Griffin SJ. A simple risk score identifies individuals at high risk of developing Type 2 diabetes: a prospective cohort study. Fam Pract. 2008;25(3):191\u20136.","journal-title":"Fam Pract"},{"issue":"9","key":"3223_CR22","doi-asserted-by":"publisher","first-page":"e0307270","DOI":"10.1371\/journal.pone.0307270","volume":"19","author":"DJ Thompson","year":"2024","unstructured":"Thompson DJ, Wells D, Selzam S, Peneva I, Moore R, Sharp K, Tarran WA, Beard EJ, Riveros-Mckay F, Giner-Delgado C, et al. A systematic evaluation of the performance and properties of the UK Biobank Polygenic Risk Score (PRS) Release. PLoS ONE. 2024;19(9):e0307270.","journal-title":"PLoS ONE"},{"issue":"14","key":"3223_CR23","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/eurheartj\/ehx254","volume":"40","author":"TJ Littlejohns","year":"2019","unstructured":"Littlejohns TJ, Sudlow C, Allen NE, Collins R. UK Biobank: opportunities for cardiovascular research. Eur Heart J. 2019;40(14):1158\u201366.","journal-title":"Eur Heart J"},{"key":"3223_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1146\/annurev-publhealth-090419-102644","volume":"42","author":"JB Echouffo-Tcheugui","year":"2021","unstructured":"Echouffo-Tcheugui JB, Selvin E. Prediabetes and what it means: the epidemiological evidence. Annu Rev Public Health. 2021;42:59\u201377.","journal-title":"Annu Rev Public Health"},{"issue":"18","key":"3223_CR25","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/hmg\/ddab109","volume":"30","author":"KE Westerman","year":"2021","unstructured":"Westerman KE, Miao J, Chasman DI, Florez JC, Chen H, Manning AK, Cole JB. Genome-wide gene-diet interaction analysis in the UK Biobank identifies novel effects on hemoglobin A1c. Hum Mol Genet. 2021;30(18):1773\u201383.","journal-title":"Hum Mol Genet"},{"issue":"7982","key":"3223_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun BB, Chiou J, Traylor M, Benner C, Hsu Y-H, Richardson TG, Surendran P, Mahajan A, Robins C, Vasquez-Grinnell SG. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023;622(7982):329\u201338.","journal-title":"Nature"},{"key":"3223_CR27","doi-asserted-by":"crossref","unstructured":"Wik L, Nordberg N, Broberg J, Bj\u00f6rkesten J, Assarsson E, Henriksson S, Grundberg I, Pettersson E, Westerberg C, Liljeroth E. Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis. Mol Cell Proteom 2021;20:100168.","DOI":"10.1016\/j.mcpro.2021.100168"},{"issue":"4","key":"3223_CR28","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bj\u00f6rkesten J, Bucht Thorsen S, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4):e95192.","journal-title":"PLoS ONE"},{"issue":"15","key":"3223_CR29","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1093\/nar\/gkr424","volume":"39","author":"M Lundberg","year":"2011","unstructured":"Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res. 2011;39(15):e102\u2013102.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3223_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41597-023-01949-y","volume":"10","author":"SC Ritchie","year":"2023","unstructured":"Ritchie SC, Surendran P, Karthikeyan S, Lambert SA, Bolton T, Pennells L, Danesh J, Di Angelantonio E, Butterworth AS, Inouye M. Quality control and removal of technical variation of NMR metabolic biomarker data in ~\u2009120,000 UK Biobank participants. Sci data. 2023;10(1):64.","journal-title":"Sci data"},{"issue":"9","key":"3223_CR31","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","volume":"50","author":"AV Khera","year":"2018","unstructured":"Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219\u201324.","journal-title":"Nat Genet"},{"issue":"4","key":"3223_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41591-020-0800-0","volume":"26","author":"N Mars","year":"2020","unstructured":"Mars N, Koskela JT, Ripatti P, Kiiskinen TTJ, Havulinna AS, Lindbohm JV, Ahola-Olli A, Kurki M, Karjalainen J, Palta P, et al. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nat Med. 2020;26(4):549\u201357.","journal-title":"Nat Med"},{"issue":"1","key":"3223_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12916-022-02354-9","volume":"20","author":"F Bragg","year":"2022","unstructured":"Bragg F, Trichia E, Aguilar-Ramirez D, Be\u0161evi\u0107 J, Lewington S, Emberson J. Predictive value of circulating NMR metabolic biomarkers for type 2 diabetes risk in the UK Biobank study. BMC Med. 2022;20(1):159.","journal-title":"BMC Med"},{"issue":"1","key":"3223_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven DJ, B\u00fchlmann P. MissForest\u2013non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012;28(1):112\u20138.","journal-title":"Bioinformatics"},{"issue":"4","key":"3223_CR35","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/sim.6370","volume":"34","author":"L Kang","year":"2015","unstructured":"Kang L, Chen W, Petrick NA, Gallas BD. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med. 2015;34(4):685\u2013703.","journal-title":"Stat Med"},{"issue":"1","key":"3223_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/EDE.0000000000000018","volume":"25","author":"KF Kerr","year":"2014","unstructured":"Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net reclassification indices for evaluating risk-prediction instruments: a critical review. Epidemiol (Cambridge Mass). 2014;25(1):114.","journal-title":"Epidemiol (Cambridge Mass)"},{"issue":"20","key":"3223_CR37","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/eurheartj\/ehae048","volume":"45","author":"L Li","year":"2024","unstructured":"Li L, Pang S, Starnecker F, Mueller-Myhsok B, Schunkert H. Integration of a polygenic score into guideline-recommended prediction of cardiovascular disease. Eur Heart J. 2024;45(20):1843\u201352.","journal-title":"Eur Heart J"},{"issue":"11","key":"3223_CR38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11892-020-01340-w","volume":"20","author":"JC Zanini","year":"2020","unstructured":"Zanini JC, Pietzner M, Langenberg C. Integrating genetics and the plasma proteome to predict the risk of type 2 diabetes. Curr Diab Rep. 2020;20(11):60.","journal-title":"Curr Diab Rep"},{"issue":"3","key":"3223_CR39","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/gim.2016.103","volume":"19","author":"K L\u00e4ll","year":"2017","unstructured":"L\u00e4ll K, M\u00e4gi R, Morris A, Metspalu A, Fischer K. Personalized risk prediction for type 2 diabetes: the potential of genetic risk scores. Genet Med. 2017;19(3):322\u20139.","journal-title":"Genet Med"},{"issue":"1","key":"3223_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/met.2019.0047","volume":"18","author":"G Satheesh","year":"2020","unstructured":"Satheesh G, Ramachandran S, Jaleel A. Metabolomics-based prospective studies and prediction of type 2 diabetes mellitus risks. Metab Syndr Relat Disord. 2020;18(1):1\u20139.","journal-title":"Metab Syndr Relat Disord"},{"issue":"8","key":"3223_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11892-019-1173-y","volume":"19","author":"JB Meigs","year":"2019","unstructured":"Meigs JB. The Genetic epidemiology of type 2 diabetes: opportunities for health translation. Curr Diab Rep. 2019;19(8):62.","journal-title":"Curr Diab Rep"},{"issue":"2","key":"3223_CR42","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2337\/db12-0495","volume":"62","author":"A Floegel","year":"2013","unstructured":"Floegel A, Stefan N, Yu Z, M\u00fchlenbruch K, Drogan D, Joost HG, Fritsche A, H\u00e4ring HU, de Hrab\u011b M, Peters A, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62(2):639\u201348.","journal-title":"Diabetes"},{"issue":"4","key":"3223_CR43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10654-018-0475-8","volume":"34","author":"C Huth","year":"2019","unstructured":"Huth C, von Toerne C, Schederecker F, de Las Heras Gala T, Herder C, Kronenberg F, Meisinger C, Rathmann W, Koenig W, Waldenberger M, et al. Protein markers and risk of type 2 diabetes and prediabetes: a targeted proteomics approach in the KORA F4\/FF4 study. Eur J Epidemiol. 2019;34(4):409\u201322.","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"3223_CR44","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00125-023-05943-2","volume":"66","author":"H Luo","year":"2023","unstructured":"Luo H, Bauer A, Nano J, Petrera A, Rathmann W, Herder C, Hauck SM, Sun BB, Hoyer A, Peters A, et al. Associations of plasma proteomics with type 2 diabetes and related traits: results from the longitudinal KORA S4\/F4\/FF4 Study. Diabetologia. 2023;66(9):1655\u201368.","journal-title":"Diabetologia"},{"issue":"4","key":"3223_CR45","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2337\/dc22-1830","volume":"46","author":"MR Rooney","year":"2023","unstructured":"Rooney MR, Chen J, Echouffo-Tcheugui JB, Walker KA, Schlosser P, Surapaneni A, Tang O, Chen J, Ballantyne CM, Boerwinkle E, et al. Proteomic predictors of incident diabetes: results from the atherosclerosis risk in communities (ARIC) study. Diabetes Care. 2023;46(4):733\u201341.","journal-title":"Diabetes Care"},{"issue":"6","key":"3223_CR46","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.2337\/dc23-2145","volume":"47","author":"P Yao","year":"2024","unstructured":"Yao P, Iona A, Pozarickij A, Said S, Wright N, Lin K, Millwood I, Fry H, Kartsonaki C, Mazidi M. Proteomic analyses in diverse populations improved risk prediction and identified new drug targets for type 2 diabetes. Diabetes Care. 2024;47(6):1012\u20139.","journal-title":"Diabetes Care"},{"issue":"2","key":"3223_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","volume":"27","author":"MJ Pencina","year":"2008","unstructured":"Pencina MJ, D\u2019Agostino Sr RB, D\u2019Agostino Jr RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157\u201372.","journal-title":"Stat Med"},{"issue":"5","key":"3223_CR48","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/CIRCULATIONAHA.104.519702","volume":"112","author":"L Tiret","year":"2005","unstructured":"Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, Schnabel R, Bickel C, Espinola-Klein C, Poirier O, et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation. 2005;112(5):643\u201350.","journal-title":"Circulation"},{"issue":"6","key":"3223_CR49","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1161\/ATVBAHA.117.309307","volume":"37","author":"C Herder","year":"2017","unstructured":"Herder C, de Las Heras Gala T, Carstensen-Kirberg M, Huth C, Zierer A, Wahl S, Sudduth-Klinger J, Kuulasmaa K, Peretz D, Ligthart S, et al. Circulating levels of interleukin 1-receptor antagonist and risk of cardiovascular disease: meta-analysis of six population-based cohorts. Arterioscler Thromb Vasc Biol. 2017;37(6):1222\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"3223_CR50","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/hc3901.096721","volume":"104","author":"Z Mallat","year":"2001","unstructured":"Mallat Z, Corbaz A, Scoazec A, Besnard S, Les\u00e8che G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001;104(14):1598\u2013603.","journal-title":"Circulation"},{"issue":"9","key":"3223_CR51","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.cardfail.2021.04.022","volume":"27","author":"RA Ferraro","year":"2021","unstructured":"Ferraro RA, Ogunmoroti O, Zhao D, Ndumele CE, Rao V, Pandey A, Larson NB, Bielinski SJ, Michos ED. Hepatocyte growth factor and incident heart failure subtypes: the multi-ethnic study of atherosclerosis (MESA). J Card Fail. 2021;27(9):981\u201390.","journal-title":"J Card Fail"},{"issue":"2","key":"3223_CR52","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jacc.2022.10.019","volume":"81","author":"M Balling","year":"2023","unstructured":"Balling M, Afzal S, Davey Smith G, Varbo A, Langsted A, Kamstrup PR, Nordestgaard BG. Elevated LDL triglycerides and atherosclerotic Risk. J Am Coll Cardiol. 2023;81(2):136\u201352.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"3223_CR53","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/s11064-013-0999-y","volume":"38","author":"M Hansen","year":"2013","unstructured":"Hansen M, Walmod PS. IGSF9 family proteins. Neurochem Res. 2013;38(6):1236\u201351.","journal-title":"Neurochem Res"},{"key":"3223_CR54","doi-asserted-by":"crossref","unstructured":"van Eekeren LE, de Mast Q, Meeder EM, Navas A, Groenendijk AL, Blaauw MJ, Vos WA, Vadaq N, Dos Santos JC, Rutten J. Plasma proteomic signatures of liver steatosis and fibrosis in people living with HIV: a cross-sectional study. EBioMedicine 2024;109:105407.","DOI":"10.1016\/j.ebiom.2024.105407"},{"key":"3223_CR55","doi-asserted-by":"publisher","unstructured":"Singh A, Ganslmeier M, Tutino M, Park Y-C, Machann J, Schick F, Peter A, Lehmann R, Wang Y, Cheng Y. Longitudinal proteogenomic analysis reveals mechanistic insights into the progression from prediabetes to type 2 diabetes. medRxiv 2026 Feb 16. https:\/\/doi.org\/10.64898\/2026.02.13.26346161","DOI":"10.64898\/2026.02.13.26346161"},{"issue":"1","key":"3223_CR56","doi-asserted-by":"publisher","first-page":"2600896","DOI":"10.1080\/29933935.2025.2600896","volume":"3","author":"Q Jiang","year":"2026","unstructured":"Jiang Q, Li J, Wu S, Zhang L, Dong L, Weng S, Tang W, Chen S. Enterococcus faecalis impairs IGSF9-dependent C1q degradation to accelerate MAFLD-HCC progression. Gut Microbes Rep. 2026;3(1):2600896.","journal-title":"Gut Microbes Rep"},{"issue":"41","key":"3223_CR57","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1038\/s41388-022-02459-8","volume":"41","author":"Y Li","year":"2022","unstructured":"Li Y, Deng Y, Zhao Y, Zhang W, Zhang S, Zhang L, Wang B, Xu Y, Chen S. Immunoglobulin superfamily 9 (IGSF9) is trans-activated by p53, inhibits breast cancer metastasis via FAK. Oncogene. 2022;41(41):4658\u201372.","journal-title":"Oncogene"},{"issue":"9733","key":"3223_CR58","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215\u201322.","journal-title":"Lancet"},{"issue":"9","key":"3223_CR59","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1038\/s41591-024-03142-z","volume":"30","author":"J Carrasco-Zanini","year":"2024","unstructured":"Carrasco-Zanini J, Pietzner M, Davitte J, Surendran P, Croteau-Chonka DC, Robins C, Torralbo A, Tomlinson C, Gr\u00fcnschl\u00e4ger F, Fitzpatrick N, et al. Proteomic signatures improve risk prediction for common and rare diseases. Nat Med. 2024;30(9):2489\u201398.","journal-title":"Nat Med"},{"issue":"7","key":"3223_CR60","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1016\/S2589-7500(24)00087-6","volume":"6","author":"J Carrasco-Zanini","year":"2024","unstructured":"Carrasco-Zanini J, Pietzner M, Koprulu M, Wheeler E, Kerrison ND, Wareham NJ, Langenberg C. Proteomic prediction of diverse incident diseases: a machine learning-guided biomarker discovery study using data from a prospective cohort study. Lancet Digit Health. 2024;6(7):e470\u20139.","journal-title":"Lancet Digit Health"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03223-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03223-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03223-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:07:37Z","timestamp":1781651257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03223-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3223"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03223-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}